Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.44 |
| ▸ | DHODH | Q02127 | 5/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1144583 | 0.81 | SMN1; SMN2 (0.50) | SMN1; SMN2HTTEGLN1DHODHCSNK2A1 | |
| SCHEMBL30888946 | 0.81 | SMN1; SMN2 (0.50) | SMN1; SMN2HTTEGLN1DHODHCSNK2A1 | |
| SCHEMBL13544184 | 0.81 | SMN1; SMN2 (0.50) | SMN1; SMN2HTTEGLN1DHODHCSNK2A1 | |
| SCHEMBL5994439 | 0.81 | HTT (0.47) | HTTDHODHFGFR1FGFR2FGFR3 | |
| SCHEMBL8265513 | 0.81 | HTT (0.47) | HTTEGLN1DHODHFGFR1FGFR2 | |
| SCHEMBL25309684 | 0.80 | EGLN1 (0.43) | SMN1; SMN2HTTEGLN1KDM4EHPGD | |
| SCHEMBL30511380 | 0.80 | EGLN1 (0.43) | SMN1; SMN2HTTEGLN1KDM4EHPGD | |
| SCHEMBL10003407 | 0.78 | HTT (0.44) | HTTDHODHFGFR1FGFR2FGFR3 | |
| SCHEMBL17276020 | 0.78 | PNP (0.44) | EGLN1CSNK2A1ALDH1A1 | |
| SCHEMBL8525153 | 0.78 | HTT (0.44) | SMN1; SMN2HTTDHODHCSNK2A1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378232-B2 | Cyclin dependent kinase inhibitors | PFIZER INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3784664-B1 | 2-AMINO-PYRIDINE OR 2-AMINO-PYRIMIDINE DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | PFIZER (US) | 2025-02-19 | — | — | EP | disclosed |
| CN-118286225-A | 2-Amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | 辉瑞公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-112313219-B | 2-Amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | 辉瑞公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-112028834-B | Synthesis method of Abelide intermediate | 济南悟通生物科技有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-20220089580-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | PFIZER INC. (US) | 2022-03-24 | — | — | US | disclosed |
| US-20220089580-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | PFIZER INC. (US) | 2022-03-24 | — | — | US | disclosed |
| US-11220494-B2 | Cyclin dependent kinase inhibitors | PFIZER INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-11220494-B2 | Cyclin dependent kinase inhibitors | PFIZER INC. (US) | 2022-01-11 | — | — | US | disclosed |
| CN-112313219-A | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | 辉瑞公司 | 2021-02-02 | — | — | CN | disclosed |
| US-20130296319-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. | 2013-11-07 | — | — | US | disclosed |
| US-8507681-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20130030181-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8288405-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2499139-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | Pfizer Inc. (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-2499140-A1 | N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | Pfizer Inc. (US) | 2012-09-19 | — | — | EP | disclosed |
| US-20120225900-A1 | N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2011058473-A1 | N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011058474-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20110111046-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER INC | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110111046-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, PC, ACACB | SMN1; SMN2 3302/4885HTT 2818/4885EGLN1 1650/4885 |
| US-20130296319-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | ACACA, PC, ACACB | SMN1; SMN2 3276/4885HTT 2862/4885EGLN1 1549/4885 |
| US-12378232-B2 | Cyclin dependent kinase inhibitors | CCNY, CCNI, CCNK | SMN1; SMN2 4086/4885HTT 3590/4885EGLN1 2213/4885 |
| US-20130030181-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, PC, ACACB | SMN1; SMN2 3302/4885HTT 2818/4885EGLN1 1650/4885 |
| US-11220494-B2 | Cyclin dependent kinase inhibitors | CCNY, CCNI, CCNK | SMN1; SMN2 4086/4885HTT 3590/4885EGLN1 2213/4885 |
| US-20220089580-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | CCNY, CCNI, CCNK | SMN1; SMN2 4086/4885HTT 3590/4885EGLN1 2213/4885 |
| US-20120225900-A1 | N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, PC, ACACB | SMN1; SMN2 3349/4885HTT 2851/4885EGLN1 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.